Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Cancer Research Stories

2013-12-13 23:04:48

New England Peptide (NEP), a Massachusetts based biotech manufacturer, and The Atlantic Cancer Research Institute (ACRI), a leading cancer research center in Atlantic Canada, have launched a new biotech company. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both NEP and ACRI for the isolation of exosomes and extracellular microvesicles. Gardner, MA (PRWEB) December 13, 2013 Vn96 is a synthetic peptide that was designed to specifically stick to...

2013-12-13 23:03:33

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses the progress being made in developing more effective treatments for a rare and deadly brain tumor that affects children under the age of 4. New York, NY (PRWEB) December 13, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by the Montreal Gazette on December 11, 2013 that discusses the progress being made...

2013-12-10 23:33:21

In response to an article published by Science Daily, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses the results of an immune system study that could lead to the cure of a hostile malignant brain tumor. New York, NY (PRWEB) December 10, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research, responds to an article published by Science Daily on November 25th, which discusses the results generated from...

2013-12-10 23:32:23

Celebrating Innovations in Cutting Edge Cancer Research Benefiting People and Pets Man's Best Friend May Find Treatments for Cancer in People New York, NY (PRWEB) December 10, 2013 On October 28, 2013, the Puccini Foundation for Comparative Oncology (http://www.puccinifoundation.org) hosted its inaugural awards event in New York City. The Shared Cancer/Shared Cures celebration honored the collaborative efforts of world renowned experts: a veterinary oncologist and a medical...

2013-12-10 23:02:39

Study shows small number of tumor mutations drive tumor growth. Only with this information, can the application of inhibitor drugs be truly targeted and effective. (PRWEB) December 10, 2013 Recent cancer research from the Program for Evolutionary Dynamics at Harvard University, under the direction of Martin Nowak and mathematics graduate student Ivan Bozic PhD, has shown that only a small percentage of a tumor’s mutations drive tumor growth. The study reveals the critical necessity of...

2013-12-10 08:31:15

EAST SETAUKET, N.Y., Dec. 10, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTC: LIXT), a clinical-stage pharmaceutical company, has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Dr. John Kovach, the founder of Lixte said "Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety...

2013-12-09 23:01:32

St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor Memphis, Tenn. (PRWEB) December 09, 2013 Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other...

2013-12-09 14:05:31

Researchers identify mechanism implicated in brain cancer and a drug that decreases brain tumor growth Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer. Despite current treatment strategies, the median survival for patients with the most aggressive brain cancer – called glioblastoma, is 15 months. Less than five per cent of patients survive beyond five years....

2013-12-09 10:14:03

Knowledge about the efficacy of the human papillomavirus (HPV) vaccine in preventing cervical cancer was lacking in the majority of survey respondents for whom the information would be relevant, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9. "HPV infection can cause cervical cancer as well as other cancers such as anal and vulvar cancers. Recent data...

2013-12-06 15:01:22

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread. The study, posted online recently in advance of publication in Cancer Research, was led by co-investigators Andries Zijlstra, Ph.D., assistant professor of Pathology, Microbiology and Immunology and Cancer Biology at Vanderbilt, and John Lewis,...